Gilead Sciences (GILD) Beats Q3 View By 3c; Accelerates $750 Million Buyback
More News related to GILD
- Gilead Sciences to Present at the Lazard Capital Markets 6TH Annual Healthcare Conference on Tuesday, November 17
- Gilead Sciences to Present at the 18th Annual Credit Suisse Healthcare Conference on Wednesday, November 11
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Gilead Sciences (GILD) and Glaxo (GSK) Announce Pulmonary Arterial Hypertension Clinical Trial
- Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
More News related to Earnings
- RailAmerica (RA) Reports Q3 EPS of $0.08
- Western Gas Partners (WES) Posts Q3 EPS of $0.30, Beats by 3c
- Kongzhong (KONG) Posts Q3 non-GAAP EPS of $0.16, Tops by 6c
- Applied Materials (AMAT) Post Better Than Expected Profit, But To Show 1,500 Workers The Door
- Ctrip.com (CTRP) Posts Q3 adj.-EPS of $0.44, Tops Views; Guides Q409 Revs
Gilead Sciences (Nasdaq: GILD) reports Q3 EPS of $0.52, 3 cents better than the analyst estimate of $0.49. Revenues for the quarter were $1.37 billion, versus the consensus of $1.32 billion.
Gilead issues $750 million accelerated buyback which is part of their $3 billion buyback they announced last year.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases.
Sign up at EasyStockAlerts.com & Make Money Today!
Related Categories
EarningsStock Buybacks
Stocks Mentioned
+0.33Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
